Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 12, 1999

View Archived Issues

Avigen reports advances in gene therapy for hemophilia A

Biogen provides update on top three proprietary products

Recent significant events at P&U summarized

Elan plans clinical trials for AD treatment

EpiGenesis focuses on development of new class of respiratory agents

Company Profile: Actinova

Inhibitors of TNF-alpha production/release in early development at Sumitomo

Meiji Milk Products reveals new antiangiogenic agents

New imidazole compounds from Taisho/Sagami inhibit PDE1

Preparation and activity of apoptosis inducers disclosed by Takara Shuzo

Bristol-Myers Squibb begins phase II testing of inlicensed quinolone

Photogen teams up with Akorn to advance development of PH-10

Potent, broad-spectrum, orally bioavailable carbapenems designed by Sankyo

Integrin alphavbeta3 antagonist findings presented by Genentech team at AHA

SUN-N5030 emerges as potent neuroprotectant from new class of dual Na+/Ca2+ channel blockers

Preclinical data reported at ASN support utility of OP-1 in treating renal disease

Mixed AMPA and glycine-site NMDA antagonist with i.v./i.p. anticonvulsant activity

Positive findings of ACTION I study presented at ASN

Genetronics and Boehringer Ingelheim enter collaborative gene therapy agreement

Phase II data support further study of VX-497 for hepatitis C

United Therapeutics completes enrollment in phase III pulmonary hypertension trial

Major U.K. biopharmaceutical company merger announced

Xenova's lead drug candidates enter phase II trials during Q3 1999

AASLD presentations support feasibility of ribozyme therapy in HCV

SDZ-RAD inhibits HBV antigen production, transcription, unlike other immunosuppressants

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...